Syncom Formulations India Ltd-$
Syncom Formulations Reports Q2 FY27 Net Profit of Rs. 2,539.55 Lakhs, up 50.79% YoY
RESULTS
▲ Positive Development
LOW RISK
📅 Filed on BSE: 13 Nov 2026, 04:59 PM IST · BSE ID: 126f8667-5909-4077-b766-1f06188513d1
View Original BSE Filing (PDF)
💡
In Simple Terms
Syncom Formulations' Q2 FY27 profit rose to Rs. 2,539.55 Lakhs, an increase of 50.79% compared to the same quarter last year.
🤖 AI Summary
- Net profit for Q2 FY27 increased by 50.79% year-on-year to Rs. 2,539.55 Lakhs from Rs. 1,684.11 Lakhs in Q2 FY26.
- Revenue from operations for the quarter ended 30 September 2026 was Rs. 13,665.72 Lakhs.
- Total comprehensive income for Q2 FY27 stood at Rs. 2,492.60 Lakhs, compared to Rs. 1,678.53 Lakhs in Q2 FY26.
- Basic earnings per equity share (EPS) for Q2 FY27 was Rs. 0.27, an increase from Rs. 0.18 in Q2 FY26.
🔢 Key Numbers - exact figures from BSE filing, not rounded
Revenue from Operations (Q2 FY27)
Rs. 13,665.72 Lakhs
12.54%
Net Profit (Q2 FY27)
Rs. 2,539.55 Lakhs
50.79%
Total Comprehensive Income (Q2 FY27)
Rs. 2,492.60 Lakhs
48.50%
Basic EPS (Q2 FY27)
Rs. 0.27
50.00%
Total Segment Asset (Half Year Ended 30 Sept 2026)
Rs. 56,588.27 Lakhs
25.42%
🏢 How This Affects the Company
The Pharmaceuticals Drugs & Formulations segment remains the primary revenue driver, contributing Rs. 14,127.28 Lakhs to segment revenue in Q2 FY27.
The company recorded a substantial increase in net profit and total comprehensive income, reflecting improved financial performance year-on-year for Q2 FY27.
👥 What This Means For Shareholders
✅
Action Required
No immediate action is required by shareholders based on this financial results filing.
👤
Who Is Affected
All shareholders are affected by the improved financial performance, with basic earnings per equity share rising to Rs. 0.27.
🔍
Management Signal
The approval of these results by the Board of Directors indicates management's commitment to reporting financial performance as per regulatory requirements.
For information only. Not investment advice. ForgeUp is not SEBI-registered.
👁 Watch List - track these upcoming events
Q3 FY27 financial results — check for sustained growth in revenue and profit.
Review segment-wise performance for Pharmaceuticals Drugs & Formulations.
Future updates on changes in current liabilities, specifically borrowings.
LOW RISK
No specific material risks or adverse events are highlighted in this financial results filing.
💡 Investor Takeaway
Syncom Formulations reported Q2 FY27 net profit of Rs. 2,539.55 Lakhs, a 50.79% increase year-on-year. Revenue from operations reached Rs. 13,665.72 Lakhs. Basic EPS for the quarter was Rs. 0.27, up from Rs. 0.18 in Q2 FY26.
⚖️ Strengths & Concerns
✅ Positives
- Net profit for Q2 FY27 increased significantly by 50.79% YoY, reaching Rs. 2,539.55 Lakhs from Rs. 1,684.11 Lakhs.
- Revenue from operations grew to Rs. 13,665.72 Lakhs in Q2 FY27, up from Rs. 12,143.51 Lakhs in Q2 FY26.
⚠️ Concerns
- Cost of materials consumed remained high at Rs. 4,597.44 Lakhs in Q2 FY27, though lower than Rs. 5,877.61 Lakhs in Q1 FY27.
- Borrowings increased to Rs. 1,552.36 Lakhs as of 30 September 2026, compared to Rs. 68.13 Lakhs as of 31 March 2026.
📅 Company Track Record
Syncom Formulations previously reported Q2 FY27 net profit of Rs. 2,539.55 Lakhs, representing a 50.79% YoY increase. This filing confirms the previously intimated results, showing consistent positive growth in net profit over the past year.
Based on publicly available historical data. For context only.
❓ Frequently Asked Questions
What was Syncom Formulations' net profit in Q2 FY27?
Syncom Formulations reported a standalone net profit of Rs. 2,539.55 Lakhs for the quarter ended 30 September 2026 (Q2 FY27).
How much did Syncom Formulations' revenue from operations increase in Q2 FY27?
Revenue from operations for Syncom Formulations was Rs. 13,665.72 Lakhs in Q2 FY27, an increase from Rs. 12,143.51 Lakhs in Q2 FY26.
What is the basic earnings per share (EPS) for Syncom Formulations in Q2 FY27?
The basic earnings per equity share for Syncom Formulations was Rs. 0.27 in Q2 FY27, up from Rs. 0.18 in Q2 FY26.
What was the total comprehensive income for Syncom Formulations in Q2 FY27?
Total comprehensive income for Syncom Formulations in Q2 FY27 was Rs. 2,492.60 Lakhs.
What was the total segment asset for Syncom Formulations as of 30 September 2026?
The total segment asset for Syncom Formulations as of 30 September 2026 was Rs. 56,588.27 Lakhs.
Questions based on this BSE filing only. For information purposes.